Business Context and Reporting Period
Company: Fresenius Medical Care AG
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Filing Date: February 25, 2025
Reporting Period: Fourth Quarter and Full Year ended December 31, 2024
This filing serves as a notification that the Company issued a press release on February 25, 2025, announcing its financial results for the fourth quarter and full year 2024. The detailed financial figures are contained in the attached exhibits (Exhibit 99.1 and Exhibit 99.2) and are not explicitly listed in the body of this Form 6-K.
Key Financial Metrics
The Form 6-K text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references the following metrics as being detailed in the attached exhibits:
- GAAP Measures: Consolidated financial results presented in accordance with International Financial Reporting Standards (IFRS).
- Non-GAAP Measures:
- EBITDA (Operating income excluding interest, taxes, depreciation, and amortization).
- Free cash flow.
- Net leverage ratio (Net debt to adjusted EBITDA).
- Results presented in constant currency.
- Results adjusted for special items.
Note: Specific values for these metrics are not present in the provided filing text and must be sourced from the attached Press Release (Exhibit 99.1) and Financial Overview (Exhibit 99.2).
Material Changes
The filing text does not disclose specific material changes, percentage growth, or declines compared to prior periods. It states that the attached press release contains the comparative data and reconciliations between non-GAAP and IFRS measures.
Guidance, Outlook, and Risks
Management Commentary: The Company utilizes non-GAAP measures to enhance the understanding of current financial performance and future prospects, citing historical consistency and comparability as the rationale for their inclusion.
Regulatory Note: The Company explicitly states that non-GAAP measures should not be used as a substitute for or considered superior to GAAP (IFRS) financial measures.
Risks and Contingencies: No specific risks or contingencies are detailed in the body of this Form 6-K. The filing notes that the attached exhibits are not deemed "filed" for purposes of Section 18 of the Exchange Act and are not subject to the liabilities of that section.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 and Full Year 2024 revenue, EBITDA, and net income figures.
- Examine Exhibit 99.2 for the complete financial overview and reconciliation of non-GAAP measures to IFRS standards.
- Verify the Net Leverage Ratio and Free Cash Flow calculations as defined in the press release.
- Check for any special items or adjustments made to the reported results that may impact year-over-year comparability.
- Confirm the constant currency impact on reported growth rates to isolate organic performance from foreign exchange fluctuations.